SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-001974
Filing Date
2021-10-01
Accepted
2021-10-01 16:06:02
Documents
12
Period of Report
2021-09-30
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K impl-20210930.htm   iXBRL 8-K 64013
  Complete submission text file 0000950170-21-001974.txt   196051

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT impl-20210930_lab.xml EX-101.LAB 19080
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT impl-20210930.xsd EX-101.SCH 2477
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT impl-20210930_pre.xml EX-101.PRE 11969
5 EXTRACTED XBRL INSTANCE DOCUMENT impl-20210930_htm.xml XML 5106
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL NEUROPHARMA INC (Filer) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 211298911
SIC: 2834 Pharmaceutical Preparations